New Ganjiang (920367) uses 94.50 million yuan of its own funds to purchase wealth-management products to improve the efficiency of using its own funds

On April 7th, Jiangxi Xin Ganjiang Pharmaceutical Co., Ltd. announced that the total amount of funds used to purchase wealth management products with part of its idle funds was 94.5 million yuan. As of now, the company’s idle funds used to purchase wealth management products have an outstanding balance of 159.2 million yuan in products that have not yet matured.

Xin Ganjiang stated in the announcement that the company held the 8th meeting of the third board of directors and the first extraordinary general meeting of 2025, during which they approved the proposal on using idle funds to purchase wealth management products. The company plans to continue using idle funds to purchase wealth management products, with the same limit, and the single purchase amount or the balance of unexpired wealth management products held at any time will not exceed 165 million yuan.

Bingbi Finance learned that the company is a pharmaceutical manufacturing enterprise engaged in the research, production, and sales of raw materials, chemical drug preparations, and Chinese patent medicines. The company’s raw material drugs mainly include calcium gluconate, zinc gluconate, ferrous gluconate, and other gluconate series raw materials, which hold a leading market share in the industry. The company’s main chemical drug preparations include vitamin C chewable tablets, compound Yin Qiao Gan Min capsules, phenylethylamine tablets, etc., which belong to vitamin and cold medicine categories; the main Chinese patent medicines include Xin Nao Kang capsules, Gan Mao Ling capsules, and Er Bao ointment, which are used for cardiovascular, cold, and tonic purposes.

The company strictly follows the “Good Manufacturing Practice for Drugs” (revised in 2010), organizing production in accordance with GMP requirements, and has established corresponding quality assurance systems based on the production characteristics of different products. It has formulated quality control standards covering all aspects from raw material procurement, semi-finished products, to finished product manufacturing, including drug research and development, material procurement, production, inspection, storage, transportation, and sales, ensuring that the quality of exported drugs meets relevant standards.

Having been deeply involved in this industry for nearly twenty years, the company has accumulated rich technical and industry experience, established a good brand image, and maintained long-term, stable, and in-depth cooperation with many large domestic pharmaceutical companies. The company’s gluconate raw material products and services are recognized by many downstream formulation enterprises in the industry, and it enjoys a high reputation and market position within the industry.

Through relentless efforts and relying on high-quality products and strict quality control systems, the company has formed long-term, stable partnerships with major domestic downstream formulation enterprises of glucose salt raw materials, including Aonu China Pharmaceutical Co., Ltd., H Group Sanjing Pharmaceutical Co., Ltd., and Hubei Furen Jinshen Pharmaceutical Co., Ltd.

Since its establishment, the company has been committed to consolidating its gluconate series raw material business and continuously extending into formulation business, aiming to build a complete health ecosystem and transform from a raw material-focused pharmaceutical enterprise into a comprehensive branded pharmaceutical company.

In recent years, the company has focused on strategic layout for its formulation business. Based on existing product approvals and leveraging current sales channels, it has gradually developed a formulation development pattern centered on vitamin and cold medicines as the core echelon, with cardiovascular, tonic, and orthopedic medicines as the reserve echelon.

In terms of performance, by 2025, the company achieved an operating revenue of 141 million yuan, a year-on-year decrease of 8.29%; net profit attributable to shareholders of the listed company was 14.5854 million yuan, a year-on-year decrease of 34.92%.